- Home
- INKT vs MRKR Comparison
INKT vs MRKR Comparison
Compare INKT & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- MRKR
- Stock Information
- Founded
- INKT 2017
- MRKR N/A
- Country
- INKT United States
- MRKR United States
- Employees
- INKT N/A
- MRKR N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- MRKR Health Care
- Exchange
- INKT Nasdaq
- MRKR Nasdaq
- Market Cap
- INKT 30.6M
- MRKR 23.1M
- IPO Year
- INKT 2021
- MRKR N/A
- Fundamental
- Price
- INKT $0.67
- MRKR $3.25
- Analyst Decision
- INKT Strong Buy
- MRKR Strong Buy
- Analyst Count
- INKT 1
- MRKR 1
- Target Price
- INKT $9.00
- MRKR $11.00
- AVG Volume (30 Days)
- INKT 49.3K
- MRKR 41.1K
- Earning Date
- INKT 11-07-2024
- MRKR 11-07-2024
- Dividend Yield
- INKT N/A
- MRKR N/A
- EPS Growth
- INKT N/A
- MRKR N/A
- EPS
- INKT N/A
- MRKR N/A
- Revenue
- INKT N/A
- MRKR $3,727,435.00
- Revenue This Year
- INKT N/A
- MRKR $35.94
- Revenue Next Year
- INKT N/A
- MRKR N/A
- P/E Ratio
- INKT N/A
- MRKR N/A
- Revenue Growth
- INKT N/A
- MRKR N/A
- 52 Week Low
- INKT $0.57
- MRKR $2.40
- 52 Week High
- INKT $1.90
- MRKR $6.16
- Technical
- Relative Strength Index (RSI)
- INKT 34.43
- MRKR 55.77
- Support Level
- INKT $0.65
- MRKR $2.44
- Resistance Level
- INKT $0.76
- MRKR $4.06
- Average True Range (ATR)
- INKT 0.04
- MRKR 0.35
- MACD
- INKT -0.00
- MRKR 0.12
- Stochastic Oscillator
- INKT 50.15
- MRKR 50.00
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.